All relevant data are in the paper and its Supporting Information files.

1 Introduction {#sec001}
==============

The long competitive season often includes a high frequency, intensity and duration of training sessions, that can place a heavy strain on biological systems of young players. Furthermore, the increase of exercise intensity, occurring as part of the success paradigm towards elite sport, could be also added to a psychophysiological stress on youth elite players \[[@pone.0236669.ref001]\].

Long-term hormonal responses to elite team sports have been reported \[[@pone.0236669.ref002]--[@pone.0236669.ref006]\]. In particular, sC, sT and their sT/C values are considered markers of exercise-related stress and balance between anabolic and catabolic processes, respectively \[[@pone.0236669.ref005],[@pone.0236669.ref007],[@pone.0236669.ref008]\]. Depending on the intensity and duration of exercise, transient increments or suppressions in immune parameters may also occur, namely those involved in mucosal immunity including sAA \[[@pone.0236669.ref009]\] and sIgA \[[@pone.0236669.ref008],[@pone.0236669.ref010]\].

Produced locally in the salivary glands and controlled by the autonomous nervous system, sAA inhibits bacterial adherence and growth to epithelial surfaces \[[@pone.0236669.ref011]\] and has been proposed as a biomarker of body stress and sympathetic nervous system activity \[[@pone.0236669.ref012]--[@pone.0236669.ref014]\]. Preventing the attachment of external pathogens to mucosal surfaces, acting as a first line of defence against microbial invasion, secretory IgA also plays an important role in mucosal immunity \[[@pone.0236669.ref012],[@pone.0236669.ref015],[@pone.0236669.ref016]\], which might be affected by strenuous bouts of intense exercise \[[@pone.0236669.ref017]\]. In particular, multiple daily intense training sessions may result in accumulative mucosal immune suppression of sIgA and srIgA \[[@pone.0236669.ref015],[@pone.0236669.ref016]\].

Exercise-induced transient suppression of immunological responses could determine an impaired immune condition \[[@pone.0236669.ref017]\] increasing the risk of contracting upper respiratory tract infections (URTI) \[[@pone.0236669.ref017]--[@pone.0236669.ref023]\]. The diagnosis of URTI is still unclear, especially in the absence of laboratory testing confirming the presence of a pathogen \[[@pone.0236669.ref017],[@pone.0236669.ref024]\]. Indeed, the term upper respiratory symptoms (URS) could be more appropriate to classify signs and symptoms affecting the upper airways \[[@pone.0236669.ref024]--[@pone.0236669.ref027]\].

Despite the many studies on various acute immunological and endocrine responses to training and competition \[[@pone.0236669.ref020],[@pone.0236669.ref028]--[@pone.0236669.ref030]\], data from seasonal monitoring of biomarkers using less invasive strategies as saliva collection is still lacking \[[@pone.0236669.ref031]\]. In this study, we will permit a better understanding of the load dynamics in the last three age-groups of the youth department and, as well, the age-groups where the game has is formal format (eleven vs. eleven). With this in mind it's possible to the coaches and researchers to highlight the mechanisms that are underpinning the training sessions and, by inference, the competition, putting all in line with the progressive demands of soccer talent development programs. Monitoring young athletes can provide valuable information to coaches about the adequacy of their training plans; the aim of this study was to examine the monthly variations of immune and hormonal mucosal parameters in young soccer players during a competitive season. It has been hypothesized that: 1) youth soccer players could show different age-related adaptive hormonal and immune responses to training and competition; 2) exercise could mediate changes in mucosal immune parameters and the incidence of upper respiratory symptoms could be related.

2 Materials and methods {#sec002}
=======================

2.1 Subjects {#sec003}
------------

Fifty-seven male young players from the same soccer club academy, playing at national level in their age group (main Portugal national championship), were recruited for this study. At the beginning of the study U15, U17 and U19 teams encompassed 28, 35 and 28 players respectively; however, some dropouts (11, 13 and 10 soccer players, respectively) occurred during the competitive season due to: the club selection program requirements, occasional maladaptation's, injury and other reasons. Thus, the final sample consisted of the seventeen Under 15 (U15: age 14.8±0.2 yrs.; stature 170.8± 6.6 cm; body mass 60.1±9.5 kg; body fat 14.8±3.8%), twenty-two Under 17 (U17, mean ± SD: age 16.1±0.4 yrs.; stature 174.4±6.7 cm; body mass 67.0±8.1 kg; body fat 14.1±3.0%) and eighteen Under 19 (U19, mean ± SD: age 18.8±0.2 yrs.; stature 177.5±6.9 cm; body mass 70.9±8.1 kg; body fat 13.3±4.9%). The recruitment of soccer players was agreed with the technical department of the soccer academy at the end of the season that preceded the study (May/June), and the study included all players from the squads of the various teams. The inclusion criteria were: a) to volunteer, as well as to authorize their tutors to participate in the study; a) integrate the team of the respective age group up to one month after the start of the season; b) do not present any physical limitation or injury that prevents them from participating in the regular training of the team. Exclusion criteria: a) the occurrence of an injury or illness that would require you to leave regular training for a period longer than 2 weeks; b) failure to participate in at least two thirds of the training plan; c) transfer to another club / team. The sample consists of players who participate in the main national competition of the respective age groups, obtaining merit sports results. The study took place in a training academy for football players belonging to one of the historic clubs of Portuguese football. The study was fully approved by the Ethics and Human Subjects Review Board of the Faculty of Sports Science and Physical Education of the University of Coimbra (Portugal) and conducted according to the Helsinki declaration (CE/FCDEF-UC/00032013). Verbal and written information on the experimental procedures were provided for all participants. Signed informed consent statements were obtained from athletes and their parents or guardians when underaged (under 16).

2.2 Design {#sec004}
----------

The study followed a longitudinal parallel design. To verify different age-related adaptive responses to training, salivary hormonal (i.e., sC, sT and sT/C) and immune parameters (i.e., sAA, sIgA, srIgA) were monitored during a competitive season spanning from July to April. The relationship between mucosal immune parameters and the incidence of URS was verified monthly, always in the first training session in the first week of each month, after two days of recovery for all teams (U15 = 8 months; U17 and U19 = 9 months).

2.3 Training and competition load {#sec005}
---------------------------------

The training load was computed by counting the time (minutes) spent in training sessions and competitions. During the experimental period, the three groups had four (U15 and U17) and five (U19) training sessions with 1.5h of duration/session plus 70-, 80- and 90-minute match per week for U15, U17 and U19, respectively. The typical training sessions consisted of warm-up, individual and group technical drills, team technical drills, circuit training and cool-down.

2.4 Procedures and data collection {#sec006}
----------------------------------

During the study period, no dietary interventions were undertaken. Players were instructed to maintain their normal daily nutritional and hydration intake. Saliva samples were collected monthly before the first training session of the week, ensuring at least 36 hours of rest from the last match or training, which enabled the recovery of acute immune and hormonal responses determined from previous exercise \[[@pone.0236669.ref032]\]. Furthermore, subjects were asked to avoid any intense exercise during the 36 hours before each experimental session and to abstain from food and caffeine products intake two hours before to saliva collection. Once at the collection site, subjects were required to rinse out their mouths with distilled water to clean the oral cavity 20 min before collection time (18.00--19.00 pm). Then, passive unstimulated whole saliva samples were collected during 3 min with athletes in a seated position and with the head tilted slightly forward, using appropriate pre-weighted and pre-labeled plastic tubes of 7mL (Sarstedt®) and immediately stored at approximately 4°C in a polystyrene container with ice, prior to transport and subsequent storage in the laboratory. Within the testing laboratory, the samples were de-identified by application of a laboratory number, weighted again to calculate saliva flow rate and they were thawed, vortexed, and centrifuged at 1,500 g (\@3,000 rpm) for 15 min as per ELISA protocol (Salimetrics, Carlsbad, CA, USA) and split into two Eppendorf tubes to allow assay re-run if required. Labeled saliva samples were frozen at −80°C within a secure, back-up powered ultra-low freezer within 4 h of collection. No additional preservatives such as sodium azide were added to the samples to exclude possible assay interference.

2.5 Salivary hormonal and immune assessments {#sec007}
--------------------------------------------

Concentrations of sC, sT, sAA and sIgA were determined using commercially available ELISA kits (*Salimetrics*, Inc., State College, PA, USA). The concentration of salivary IgA was expressed in term of: 1) the absolute concentration of salivary IgA (μg · ml^-1^) and 2) the salivary IgA secretion rate (μg · min^-1^). The salivary IgA secretion rate was calculated by multiplying the absolute salivary IgA concentration (μg · ml^-1^) by the salivary flow rate (ml · min^-1^); this latter value was calculated by dividing the total volume of each saliva sample (ml) by the time taken to collect each sample (3 min). Salivary secretion rate was calculated from saliva flow rate (ml.min^-1^), which was determined dividing the saliva volume by the collection time. Saliva flow rate of valid samples should not be \<0.1 ml.min^-1^. Under basal conditions, the rate of saliva production is 0.5 ml.min^-1^ \[[@pone.0236669.ref033]\]. All samples belonging to the same athlete were tested in the same plate to reduce inter-assay variations and in duplicate. The intra-assay maximum coefficient of variation was 6.7% for sAA, 3.65% for sC, 3.3% for sT and 3.3% for sIgA. The inter-assay maximum coefficient of variation was 5.8% for sAA, 6.41% for sC, 8.1% for sT and 7.9% for sIgA.

2.6 Monitoring of URS episodes {#sec008}
------------------------------

Subjects were required to fill a monthly log to document any signs or symptoms of URS including cold, cough, nasal secretion, headache, sore throat, muscle pain, diarrhoea, abdominal pain, cold shivers, itchy eyes, sneezing and fever. The athletes' information was compared with that provided from their respective coaches, to eventually confirm the reported URS occurrence. When a sign of illness was reported the WURSS-21 \[[@pone.0236669.ref034]\] was applied. This questionnaire was developed to comprehensively measure all significant health-related dimensions that are negatively affected by the common cold. A conservative method of identifying URS was used. The logging of an episode required a report of two or more cold-specific symptoms during at least two days in a row. A new episode was considered after a minimum interval of 10 days following the previous one \[[@pone.0236669.ref035]\]. Symptoms related to allergic episodes (itchy eyes, sneezing), gastrointestinal or muscular pain related to injuries were carefully analysed and discarded \[[@pone.0236669.ref024],[@pone.0236669.ref027]\].

2.7 Statistical analysis {#sec009}
------------------------

Descriptive statistics was computed as mean and standard deviation (mean ± SD). The Chi-square test was used to compare time spent in training and competition and URS occurrence of the 3 soccer groups. Accounting for non-normal distribution and small sample size the Friedman test analysed the within repeated measures and Kruskal-Wallis test was used for between comparisons. Pairwise multiple comparisons were conducted with the adjustment by Dunn test originally designed first for Kruskal-Wallis test, able to use in non-parametric repeated measures and incorporated in SPSS 21.0. Effect size was used to ascertain magnitude of the difference of the mean as trivial (0--0.19), small (0.20--0.49), medium (0.50--0.79), large (0.80 and greater) \[[@pone.0236669.ref036]\]. We calculated the a priori statistical power. For an α = 0.05 and moderate effect size (*es* = 0.5), the sample size of our study assures an β of 0.84 (84%) using G\*Power Version 3.1.9.2. The exploration of association between biomarkers and URS was done through Spearman Rho (p≤ 0.05). Statistical analysis was performed using the software package (IBM SPSS, version 21.0, 2012), with statistical significance set at (p≤ 0.05).

3 Results {#sec010}
=========

3.1 Training load {#sec011}
-----------------

Regarding the monthly distribution of exercise volume in each group, the U15 highest percentages emerged in October (12.3%), whereas the relative picture for both U17 (18.6%) and U19 (14.5%) was in August (above each group seasonal training volume average). This distribution fits with the previous pre-season overload of both U17 and U19 and mimics the incremental approach planned for the youngest group (U15), which performs a higher volume later. [Table 1](#pone.0236669.t001){ref-type="table"} shows detailed data of the monthly exercise volume (minutes) spent in training and matches. A seasonal training volume variation for all groups are presented in the [Fig 1](#pone.0236669.g001){ref-type="fig"}.

![Seasonal training volume variation of young soccer players (U19, U17 and U15) across a soccer season.\
Data are % variation per group.](pone.0236669.g001){#pone.0236669.g001}

10.1371/journal.pone.0236669.t001

###### Monthly training volume and matches of each soccer team (U15, U17 and U19).

![](pone.0236669.t001){#pone.0236669.t001g}

              Under-15     Under-17    Under-19                                                                    
  ----------- ------------ ----------- ------------ ------------ ----------- ------------ ------------ ----------- ------------
  August      1440         280         1720         1730         450         2180         1820         360         2180
  September   1530         280         1810         1500         270         1770         1530         450         1980
  October     1620         280         1900         1660         270         1930         1805         270         2075
  November    1080         280         1360         1520         360         1880         1455         270         1725
  December    1440         210         1650         1270         360         1630         1385         270         1655
  January     1350         280         1630         1760         270         2030         1740         360         2100
  February    1530         280         1810         1455         270         1725         1440         180         1620
  March       1440         210         1950         1235         360         1595         1355         540         1895
  April       \-           \-          \-           1445         360         1805         1365         360         1725
  *Mean*      *1428*,*8*   *262*,*5*   *1691*,*3*   *1508*,*3*   *330*,*0*   *1838*,*3*   *1566*,*3*   *340*,*0*   *1903*,*8*
  *SD*        *162*,*7*    *32*,*4*    *164*,*5*    *185*,*1*    *63*,*6*    *188*,*7*    *192*,*2*    *115*,*4*   *215*,*3*
  *CV*        *11*,*4*     *12*,*3*    *9*,*7*      *12*,*3*     *19*,*3*    *10*,*3*     *12*,*3*     *33*,*9*    *11*,*3*

3.2 URS occurrence {#sec012}
------------------

Higher URS occurrence emerged for U15 team (40 episodes,44.9% of the total) compared to U17 (33 episodes, 37.1% of total) and U19 (16 episodes, 18% of the total) (Z = 6.47; P = 0.039; [Fig 2](#pone.0236669.g002){ref-type="fig"}). A significant inverse association was found between URS with srIgA (r = -0.170, p = .001), sAA (r = -0.179, p = .001) and sT (r = -0.107, p = .047). Furthermore, the correlation between the number of URS events and the age group (r = -0.180, *p*\< .001) showed that there was a trend to younger players were more prone to get an URS episode.

![Upper respiratory symptoms occurrence in young soccer players (U19, U17 and U15) across a soccer season.\
Data are: A) URS occurrence of number of episodes in each group per month; B) URS occurrence of % total number of episodes of total group per month.](pone.0236669.g002){#pone.0236669.g002}

3.3 Seasonal variation of salivary biomarkers {#sec013}
---------------------------------------------

[Table 2](#pone.0236669.t002){ref-type="table"} reports the comparative analysis of the immunological and endocrine biomarkers values (mean and standard deviation) and the groups comparisons, whereas [Fig 3](#pone.0236669.g003){ref-type="fig"} (Graphs A-F) show the pattern across time for the physiological parameters, which highlights the most critical variation of the study variables during the soccer season in the three soccer teams.

![Salivary immune and hormonal responses of young soccer players (U19, U17 and U15) across a soccer season.\
Data are Mean + SD (standard deviation). \* P \< 0.05 between U15 and U17. \# P \< 0.05 between U17 and U19. & P \< 0.05 between U15 and U19. Abbreviations: U15: Under-15 yrs, U17: Under-17 yrs, U19: Under-19 yrs.](pone.0236669.g003){#pone.0236669.g003}

10.1371/journal.pone.0236669.t002

###### Salivary immune and hormonal responses (S-IgA, Sr-IgA, S-AA, S-C, S-T and S-T:C ratio) of young soccer players (U19, U17 and U15) across a soccer season.

![](pone.0236669.t002){#pone.0236669.t002g}

                          Aug                                                 Sep                                                                                   Oct                                                                                                                               Nov                                                 Dec                                                                                    Jan                                                                                                                                    Feb                                                                                      Mar                                                                                            Apr
  ----------------------- --------------------------------------------------- ------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------
  **Under 15 (n = 17)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  S-IgA (mg.dL^-1^)       279.3 (97.1)                                        302.1 (95.2)                                                                          285.6 (70.0)                                                                                                                      240.7 (124.9)                                       224.3 (132.4)                                                                          391.2(189.7)[^e^](#t002fn006){ref-type="table-fn"}                                                                                     248.6 (101.6)                                                                            280.5 (136.8)                                                                                  
  sr-IgA (μg.min^-1^)     98.5 (54.9)                                         85.4 (31.6)                                                                           78.0 (30.2)                                                                                                                       72.1 (26.2)                                         84.5 (58.2)                                                                            108.5 (59.5)                                                                                                                           65.6 (34.5)[^f^](#t002fn007){ref-type="table-fn"}                                        74.9 (33.4)                                                                                    
  S-AA (U.mL^-1^)         95.6 (60.5)                                         87.1 (45.9)                                                                           97.8 (49.1)                                                                                                                       81.1 (40.4)                                         115.3 (57.0)                                                                           109.6 (109.9)                                                                                                                          116.2 (72.8)                                                                             93.9 (59.1)                                                                                    
  S-C (g/mL)              208.7 (82.4)                                        195.3 (77.9)                                                                          132.4 (82.4)[^a^](#t002fn002){ref-type="table-fn"}                                                                                144.5 (124.8)                                       124.3 (98.1)                                                                           119.6 (48.7)                                                                                                                           154.3 (43.0)                                                                             165.6 (119.9)                                                                                   
  S-T (ng/mL)             87.3 (34.5)                                         69.6 (30.2)                                                                           65.9 (29.6)                                                                                                                       67.8 (21.6)                                         53.3 (18.0)                                                                            110.2 (60.2)[^c^](#t002fn004){ref-type="table-fn"}^,^[^d^](#t002fn005){ref-type="table-fn"}^,^[^e^](#t002fn006){ref-type="table-fn"}   72.9 (15.5)                                                                              65.6 (27.9)                                                                                    
  S-T:C                   0.49 (0.28)                                         0.45 (0.37)                                                                           0.62 (0.32)                                                                                                                       0.69 (0.31)                                         0.74 (0.62)                                                                            1.25 (1.21)                                                                                                                            0.51 (0.20)                                                                              0.49 (0.24)[^c^](#t002fn004){ref-type="table-fn"}[^f^](#t002fn007){ref-type="table-fn"}         
  **Under 17 (n = 22)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  S-IgA (mg.dL^-1^)       368.3 (229.5)                                       239.6 (117.9)                                                                         289.8 (151.4)                                                                                                                     256.8 (153.1)                                       270.3 (146.2)                                                                          245.9 (128.4) [£](#t002fn012){ref-type="table-fn"}                                                                                     293.8 (134.4)                                                                            247.9 (117.5)                                                                                  227.0 (96.5)
  sr-IgA (μg.min^-1^)     68.5 (41.1)                                         69.0 (41.6)                                                                           72.5 (53.0)                                                                                                                       99.8 (58.1)                                         120.8 (107.6)                                                                          89.2 (45.5)                                                                                                                            121.2 (102.6)                                                                            91.2 (90.3)                                                                                    63.1 (41.8)
  S-AA (U.mL^-1^)         54.5 (42.4)                                         45.6 (43.9)[£](#t002fn012){ref-type="table-fn"}                                       54.4 (57.6)[£](#t002fn012){ref-type="table-fn"}                                                                                   67.6 (99.5)                                         41.2 (36.3)[£](#t002fn012){ref-type="table-fn"}                                        55.5 (60.1)                                                                                                                            58.3 (65.6)                                                                              33.9 (43.0)[£](#t002fn012){ref-type="table-fn"}                                                47.3 (36.5)
  S-C (ng/mL)             130.5 (107.8)[£](#t002fn012){ref-type="table-fn"}   85.8 (63.0)[£](#t002fn012){ref-type="table-fn"}                                       56.0 (39.6)[£](#t002fn012){ref-type="table-fn"}                                                                                   66.3 (54.7)[£](#t002fn012){ref-type="table-fn"}     49.1 (34.0)[£](#t002fn012){ref-type="table-fn"}                                        83.2 (41.6)                                                                                                                            84.1 (45.6)[£](#t002fn012){ref-type="table-fn"}                                          119.3 (77.0)                                                                                   101.1 (78.1)
  S-T (ng/mL)             84.8 (21.0)                                         65.5 (19.0)                                                                           71.5 (26.6)                                                                                                                       64.8 (21.8)                                         60.5 (17.0)                                                                            75.3 (27.0)[£](#t002fn012){ref-type="table-fn"}                                                                                        107.3 (64.5)                                                                             80.1 (28.3)                                                                                    64.0 (20.4)
  S-T:C                   1.17 (1.0) [£](#t002fn012){ref-type="table-fn"}     1.14 (0.94)[£](#t002fn012){ref-type="table-fn"}                                       1.57 (0.87)[^g^](#t002fn008){ref-type="table-fn"}^,^[^h^](#t002fn009){ref-type="table-fn"} [£](#t002fn012){ref-type="table-fn"}   1.22 (0.56) [£](#t002fn012){ref-type="table-fn"}    1.80 (1.16)[£](#t002fn012){ref-type="table-fn"}                                        1.36 (1.53)                                                                                                                            1.40 (0.63) [£](#t002fn012){ref-type="table-fn"}                                         1.13 (1.05)                                                                                    1.10 (0.92)
  **Under 19 (n = 18)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  S-IgA (mg.dL^-1^)       352.2 (111.2)                                       241.8 (66.8)                                                                          287.4 (145.5)                                                                                                                     277.9 (137.7)                                       281.2 (128.5)                                                                          290.9 (85.3)                                                                                                                           251.8 (126.3)                                                                            286.4 (116.1)                                                                                  251.5 (91.5)
  Sr-IgA(μg.min^-1^)      154.3 (104.3)[¥](#t002fn011){ref-type="table-fn"}   145.5 (80.6)[¥](#t002fn011){ref-type="table-fn"}                                      117.8 (103.9)                                                                                                                     153.6 (90.1)[£](#t002fn012){ref-type="table-fn"}    170.6 (136.0)                                                                          150.3 (98.5)                                                                                                                           120.0 (95.5)                                                                             103.7 (57.2)                                                                                   118.0 (83.1)[¥](#t002fn011){ref-type="table-fn"}
  S-AA (U.mL^-1^)         54.9 (51.6)                                         56.2 (47.7)                                                                           74.2 (73.6)                                                                                                                       91.3 (99.4)                                         61.1 (44.8)[£](#t002fn012){ref-type="table-fn"}                                        71.2 (42.8)                                                                                                                            54.9 (52.7)                                                                              37.5 (27.0) [^b^](#t002fn003){ref-type="table-fn"}                                             60.0 (46.9)
  S-C (ng/mL)             232.5 (175.9)                                       243.9 (163.0)[¥](#t002fn011){ref-type="table-fn"}                                     226.1(133.3)[¥](#t002fn011){ref-type="table-fn"}                                                                                  179.1 (138.2)[¥](#t002fn011){ref-type="table-fn"}   236.4 (175.2)[¥](#t002fn011){ref-type="table-fn"}                                      222.9 (126.5)[¥](#t002fn011){ref-type="table-fn"}                                                                                      99.3 (50.4)[¥](#t002fn011){ref-type="table-fn"}                                          292.7 (191.2) [^g^](#t002fn009){ref-type="table-fn"}^,^ [¥](#t002fn011){ref-type="table-fn"}   256.0 (210.2)[¥](#t002fn011){ref-type="table-fn"}
  S-T (ng/mL)             90.5 (30.7)                                         95.4 (20.9)[¥](#t002fn011){ref-type="table-fn"}[£](#t002fn012){ref-type="table-fn"}   87.7 (19.1)                                                                                                                       82.1 (21.4)                                         90.8 (29.6)[¥](#t002fn011){ref-type="table-fn"},[£](#t002fn012){ref-type="table-fn"}   87.9 (21.3)                                                                                                                            121.4 (39.0)[£](#t002fn012){ref-type="table-fn"}                                         97.9 (36.3)[£](#t002fn012){ref-type="table-fn"}                                                98.4 (33.9)[¥](#t002fn011){ref-type="table-fn"}
  S-T:C                   0.68 (0.69)                                         0.73 (0.67)                                                                           0.64 (0.63) [¥](#t002fn011){ref-type="table-fn"}                                                                                  0.92 (0.91) [¥](#t002fn011){ref-type="table-fn"}    0.68 (0.60) [¥](#t002fn011){ref-type="table-fn"}                                       0.66 (0.72)[¥](#t002fn011){ref-type="table-fn"}                                                                                        1.36 (0.46) [^h^](#t002fn009){ref-type="table-fn"}[£](#t002fn012){ref-type="table-fn"}   0.57 (0.67)[¥](#t002fn011){ref-type="table-fn"}                                                0.70 (0.69)

Data are mean (SD).

^a^ significant difference with August

^b^ significant differences with September

^c^ significant difference with October

^d^ significant difference with November

^e^ significant difference with December

^f^ significant difference with January

^g^ significant difference with February

^h^ significant difference with March

^i^ significant difference with April, (p\<0.05).

^¥^ significant difference with U-17

^£^ significant difference with U-15, p\<0.05.

### 3.3.1 Salivary IgA(sIgA) and secretion rate (srIgA) {#sec014}

Significant difference (χ^2^ = 16.200; *p* = .023) was found for sIgA concentration in U15 team with higher concentration values in January compared to December (*p* = .008, ES = 1.03 \[0.25, 1.8\]) ([Table 2](#pone.0236669.t002){ref-type="table"}). Inter-group sIgA comparisons showed only difference between U15 and U17 in January (*p* = .016, ES = 0.92 \[0.25, 1.58\]), whereas no seasonal differences emerged for sIgA and srIgA between U17 and U19 ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3A and 3B](#pone.0236669.g003){ref-type="fig"}). Across the season, higher srIgA values were found in the U19 compared to the U17 in August (*p* = .005, ES = 1.12 \[0.45, 1.79\]), September (*p* = .001, ES = 1.23 \[0.55, 1.90\]) and April (*p* = .011, ES = 0.86 \[0.21, 1.51\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3B](#pone.0236669.g003){ref-type="fig"}). Additionally, the U19 showed higher srIgA values with respect to U15 in November (*p* = .018, ES = 1.21 \[0.49, 1.93\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3B](#pone.0236669.g003){ref-type="fig"}).

### 3.3.2 Salivary alpha-amylase (sAA) {#sec015}

The U15 and U17 groups showed a stable response for sAA along the season, while the U19 presented significant variation (χ^2^ = 16.711; *p* = .033) with the values found in March (by the end of the season) clearly lower than from those registered in September (*p* = .037, ES = ^-^0.48 \[-1.15, 0.18\]) ([Table 2](#pone.0236669.t002){ref-type="table"}). Differences between U15 and U17 were observed in September (*p* = .011, ES = 1.02 \[0.34, 1.69\]), October (*p* = .014, ES = 0.80 \[0.14, 1.45\]), December (*p* \< .001, ES = 1.59 \[0.87, 2.32\]) and March (*p* = .002, ES = 1.86 \[0.50, 1.87\]) whilst differences between U15 and U19 were observed in December (*p* = .034, ES = 1.06 \[0.35,1.77\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3C](#pone.0236669.g003){ref-type="fig"}).

### 3.3.3 Salivary cortisol (sC) {#sec016}

The U15 showed a significant variation during the season (χ^2^ = 15.309, *p* = .032) with higher values early in the season (August compared to October) (*p* = .032, ES = 0.93 \[0.2, 1.63\]). No differences were observed for sC in the U17 group along the season. The U19 group also exhibit significant variation during the season (χ^2^ = 16.133; *p* = .041) reaching higher values in March compared to February (*p* = .018, ES = 1.32 \[-2.15, -0.48\]) ([Table 2](#pone.0236669.t002){ref-type="table"}).

Comparing the team's data along the season, the U17 showed lower sC than the U19 and U15 groups (*p* \< .001) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3D](#pone.0236669.g003){ref-type="fig"}). Looking at the monthly variation, U17 compared to U19 registered lower concentrations of sC in September (*p* = .001, ES = 1.33 \[0.64, 2.02\]), October (*p* \< .001, ES = 1.81 \[1.07, 2.55\]), November (*p* = .012, ES = 0.85 \[0.19, 1.51\]), December (*p* \< .001, ES = 1.56 \[0.85, 2.27\]), January (*p* = .002, ES = 1.55 \[0.84, 2.26\]), February (*p* = .008, ES = 0.32 \[-0.31, 0.94\]), March (*p* = .007, ES = 1.23 \[0.55, 1.97\]) and April (*p* = .019, ES = 1.01 \[0.35, 1.68\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3D](#pone.0236669.g003){ref-type="fig"}). Compared to U15, U17 had lower concentrations in August (*p* = .003, ES = 0.8 \[0.14, 1.45\]), September (*p* = .003, ES = 1.56 \[0.84, 2.29\]), October (*p* = .012, ES = 1.23 \[0.54, 1.92\]), November (*p* = .038, ES = 1.11 \[0.44, 1.78\]), December (*p* = .011, ES = 1.08 \[0.41, 1.76\]) and February (*p* = .001, ES = 0.54 \[0.10, 1.18\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3D](#pone.0236669.g003){ref-type="fig"}). No differences were found for the cortisol concentration between the U15 and U19 groups ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3D](#pone.0236669.g003){ref-type="fig"}).

### 3.3.4 Salivary testosterone (sT) {#sec017}

In the U15 the sT showed seasonal variation (χ^2^ = 26.667; *p* \< .001) with the highest value in January, that was significantly different from October (*p* = .035, ES = 0.93 \[0.23, 1.64\]), November (*p* = 0.022, ES = 0.94 \[0.23, 1.65\]) and December (*p* = .008, ES = 1.28 \[0.54, 2.02\]) ([Table 2](#pone.0236669.t002){ref-type="table"}). Furthermore, differences in sT concentrations were found between U15 and U19 in September (*p* = .001, ES = 0.99 \[0.3, 1.7\]), December (*p* \< .001, ES = 1.52 \[0.76, 2.27\]), February (*p* = .002, ES = 1.61 \[0.85, 2.38\]) and March (*p* = .039, ES = 0.99 \[0.29, 1.70\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3E](#pone.0236669.g003){ref-type="fig"}). Whilst sT differences between U15 and U17 teams were observed only in January (*p* = .0016, ES = 0.78 \[0.13, 1.44\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3E](#pone.0236669.g003){ref-type="fig"}). The sT concentrations in the U17 and U19 teams differed significantly in September (*p* = .002, ES = 1.5 \[0.8, 2.21\]), December (*p* = .004, ES = 1.29 \[0.60, 1.94\]) and April (*p* = .005, ES = 1.26 \[0.58, 1.94\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3E](#pone.0236669.g003){ref-type="fig"}).

### 3.3.5 Salivary testosterone to cortisol ratio (sT/C) {#sec018}

The U15 team showed significant variation in this anabolic:catabolic ratio (χ2 = 24.470; *p* = .002) that was lower in March compared to October (*p* = .035, ES = 0.48 \[-0.20, 1.16\]) and January (*p* = .001, ES = 0.88 \[0.18, 1.59\]) ([Table 2](#pone.0236669.t002){ref-type="table"}). The U17 team showed differences over the season (χ2 = 21.504; *p* = .006) with higher values in October when compared to the end of the season in March (*p* = .037, ES = 0.29 \[-0.3, 0.89\]) and April (*p* = .037, ES = -0.48 \[-1.08, 0.12\]) ([Table 2](#pone.0236669.t002){ref-type="table"}). The U19 team also showed a significant variation (χ2 = 17.128; *p* = .029) with the highest values in February when compared to those observed in March (*p* = .022, ES = -1.37 \[0.65, 2.1\]) ([Table 2](#pone.0236669.t002){ref-type="table"}).

Several differences were found between groups in the sT/C ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3F](#pone.0236669.g003){ref-type="fig"}). The U17 team had higher values than U19 team in October (*p* \< .001, ES = 1.01 \[0.34, 1.67\]), November (*p* = .030, ES = -0.3 \[-0.94, 0.31\]), December (*p*\<0.001, ES = -1.8 \[-1.85,-0.3\]), January (*p* = -.008, ES = -0.57 \[-1.2, 0.06\]) and March (*p* = .003, ES = -0.62 \[-1.26, 0.02\]); when compared to the U15 team, higher values were found in August (*p* = .046, ES = 0.8 \[0.14, 1.46\]), September (*p* \< .001, ES = 0.87 \[0.21, 1.53\]), October (*p* = .005, ES = 1.08 \[0.40, 1.75\]), November (*p* = .046, ES = 0.91 \[0.25, 1.57\]), December (*p* \< .001, ES = 1.1 \[0.42, 1.78\]) and February (*p* = .001, ES = 1.81 \[1.06, 2.56\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3F](#pone.0236669.g003){ref-type="fig"}). Between the U19 and U15 teams, increased values in the older group were only found in February (*p* = .001, ES = 2.37 \[1.51, 3.24\]) ([Table 2](#pone.0236669.t002){ref-type="table"}, [Fig 3F](#pone.0236669.g003){ref-type="fig"})

3.4 Training load and salivary biomarkers {#sec019}
-----------------------------------------

The total volume of training showed a positive correlation with mean sIgA concentrations (r = 0.104, *p* = .036), whereas the total volume of competitions correlated negatively with sAA enzyme activity (r = -0.138, *p* = .006).

4 Discussion {#sec020}
============

To our knowledge, this is the first study that monitored the occurrence of URS, the immune and hormonal responses during an entire soccer season in relation to the training and competition load of three age-groups of youth players belonging to the same soccer academy. Main findings highlighted tendencies to associations between training volume, salivary biomarkers and URS occurrence.

4.1 Seasonal training load variation {#sec021}
------------------------------------

We observed a stable training volume in each group across de season ([Table 1](#pone.0236669.t001){ref-type="table"}). The CV of the total volume was 9,7%, 10,3% and 11.3% for U-15, U-17 and U-19 respectively. These CV was lower than that observed in Portuguese professional soccer players \[[@pone.0236669.ref037]\]. Valente-dos-Santos and co-authors \[[@pone.0236669.ref038]\] showed that the overall training demand in soccer tends to stabilize after the player's peak height velocity.

4.2 Immune and hormonal responses along the training season {#sec022}
-----------------------------------------------------------

### 4.2.1 Salivary immune parameters {#sec023}

Considering all collected immune data over the season in the three age-group teams, we observed that the U19 team tended to show higher mean srIgA values than the younger teams and the opposite behavior for the sAA mean concentration.

Looking for the seasonal variation in each age-group, in the U15 team, sIgA showed the lowest value in December. This is in line with the observed pattern in rugby players during an eleven months season \[[@pone.0236669.ref031]\], where lower IgA levels were found in December and explained by a period of increased training intensity and reduced match activity, the same as was observed in U15 team. Although not statistically significant, the U19 team also showed a trend toward a decrease in srIgA in the last three months of the season. This behavior could be linked to the cumulative impact of a phase of intense training load and the cold weather conditions at this time of the year in the Northern hemisphere. Similarly, a study showed that sIgA had a significant decline in professional English Premier League soccer players during an intensive winter training period \[[@pone.0236669.ref039]\]. These results have practical relevance because they demonstrate that sIgA provides a non-invasive assessment that is simultaneously sensitive to the changes to either physical and/or psychological stress \[[@pone.0236669.ref028]\] associated with a winter short-term period of intensive competition.

U19 showed marked sAA differences along the training season (Mar *vs* Sep). It is possible to speculate that sAA significantly changes due to physiological and psychological stress in acute conditions \[[@pone.0236669.ref038]\]. In endurance sports, sAA acts as a potential marker of training overload \[[@pone.0236669.ref040]\] and adaptation \[[@pone.0236669.ref041]\], but in team sports the prevailing idea is that sAA is probably not very responsive and not very useful for longitudinal monitoring of the immune response. In fact, a prolonged period of training and the participation in a high number of matches could lead to a lower anti-microbial defense, affecting the immune response of young players. This could be seen in the U19 teams that showed a tendency of decrease in sAA values in March, the most stressful competitive month for this team.

### 4.2.2 Salivary hormonal parameters {#sec024}

The current study highlighted that U19 increased sC values in March and in April, which could be explained by the participation to decisive matches. In fact, training records showed that March was highly demanding, with a sequence of nine matches, being all decisive for the main goal of the season. The stress was also elevated at the end of the season, when match outcomes were important to maintain the U19 in the first division of the national championship, players were also stressed with that decisive phase. The higher sC values found in U19 compared to U17 and U15 could also be due to the higher competitive demands of their championship.

The U15 team showed higher sT levels and sT/C ratio in January compared to August. It could be possible to speculate that the rest days during the Christmas vacations helped the recovery process and consequently the immune and hormonal systems, allowing an increase in the anabolic response. The antagonist role of the stress hormone cortisol on mucosal immunity \[[@pone.0236669.ref031]\] was not confirmed in this study. The scarce variation observed throughout the season for the sC levels did not seem to contribute to the impairment in mucosal immunity. Probably, this group of young soccer players responded well to the stress situations related to training and competition. In general, a tendency for the stabilization of the hormonal system in the U15 was observed. Among the teams, U17 presented small variations in the studied biomarkers. The hormonal response of these young soccer players seems to be well adapted to their regular training workload and matches, one probability could be the "natural selection" process and for this reason was more resilient with respect to their youngest counterparts. It could be hypothesized that players more prone to illness could have dropped out soccer or were not selected for the U17 team. As expected, the U19 tended to show higher sT concentrations compared to the younger groups throughout the competitive season.

The usefulness of the individual hormonal response in team sport athletes for an early detection of maladaptation's over extended periods is controversial. The apparent antagonist role of cortisol and testosterone has already been discussed \[[@pone.0236669.ref011],[@pone.0236669.ref028]\]. Results from longitudinal studies have been equivocal and included a rise in sC during a soccer season \[[@pone.0236669.ref006]\], whereas a reduction in sC and an increase in sT/C were observed during 12 weeks of Australian Football season \[[@pone.0236669.ref002]\]. Low sC values have been associated to a good recovery, indicating the best moment to increase the training intensity \[[@pone.0236669.ref042]\]. Also, increases in the testosterone concentration reflect a good recovery of the athletes, thus enabling an increment in training load \[[@pone.0236669.ref043],[@pone.0236669.ref044]\]. Conversely, high cortisol levels have been related to the exhaustion of adrenal glands, associated to extreme fatigue \[[@pone.0236669.ref045]\].

4.3 Immune and Hormonal changes and URS occurrence {#sec025}
--------------------------------------------------

The demands of modern elite soccer, where the weekly microcycle presents several training units and often more than one competition, make players more likely to experience repeated stress situations with a limited opportunity to recover, resulting in decreases in sIgA concentrations and increases in the risk for URTIs occurrence \[[@pone.0236669.ref046]\]. Youth elite soccer players undergo weekly training plans that mimic those of adult elite players. In fact, soccer clubs support early specialization of potential elite players to have, as soon as possible, important revenues \[[@pone.0236669.ref047]\]. The tendency of inverse association of srIgA levels and URS occurrence between the volumes of training observed in this study reinforces the concept that youth athletes should be exposed to a training load adequate to their age \[[@pone.0236669.ref001]\]. In fact, the higher occurrence of URS in the U15 players compared to their older counterparts could reflect the difficulties in the adaptation of the immune system related to training during their competitive year. Conversely, players older than 15 years might have a stronger immune response possibly because of a natural sports selection process, which retains the more resilient athletes. In Portugal the highest seasonal prevalence of URS occurs in January \[[@pone.0236669.ref048]\]. In the current season, the epidemic flu period occurred between the last week of December and the end of February, with the weekly highest incidence rate observed in the end of December. This could explain the incidence rate our study, namely regarding December. In December, more than 50% of the soccer players showed a concurrent depression in their immunity with low salivary IgA concentrations. This inverse relationship between IgA concentration and cases of URS has already been reported in literature \[[@pone.0236669.ref018],[@pone.0236669.ref020],[@pone.0236669.ref028],[@pone.0236669.ref031]\]. In the U17 players, 20% of the athletes showed symptoms of respiratory illness in September, despite the lower accumulation of training and the low incidence of respiratory infection symptoms in the Portuguese population. In the Under-19 players, the pattern was closer to the one database \[[@pone.0236669.ref048]\]. Despite the high incidence of cold cases in the Portuguese population in January, regular intense soccer training could be a co-factor that helped explain the increase in URS in these athletes. Finally, the higher URS occurrence in youth players with respect to their older counterparts could be associated with periods of increased stress and training accumulation, resulting independent from environmental conditions. It is likely that young athletes more prone to illness could have dropped out of soccer or have failed the selection for the following championships.

5 Conclusions {#sec026}
=============

The current study confirmed that youth soccer players show different age-related adaptive hormonal and immune responses to training and competition. There is an association between training load (volume), mucosal immunity, hormone levels and URS. The monitoring of salivary biomarkers is a noninvasive strategy that identified periods when decreases in salivary IgA and testosterone indicate impaired health, which in turn could affect performance mainly in younger athletes at the beginning of a serious competitive career. A stimulating effect of testosterone on sIgA and of cortisol on sAA was observed, also confirming that mucosal immune parameters and incidence of upper respiratory symptoms are related. The monitoring of sIgA, testosterone and α-amylase levels could provide a useful and non-invasive approach associated to URS susceptibility and occurrence in young athletes during an entire soccer season, helping detect those more prone to illness. With this knowledge, coaches can potentially manipulate daily training loads to attenuate the physical stressors imposed upon the athletes and thereby decrease the likelihood of URS occurrence, especially at more demanding and stressful periods. In considering that in youth soccer players the prevalence of URS is higher with respect to the seasonal influence of severe weather conditions, coaches are urged to consider the effect of accumulation of training load and matches on the athletes' immune response.

Limitations of this study {#sec027}
-------------------------

In this study some limitations must be acknowledged. First, the quantification of training load was limited to the volume of training and time spent in competition, not considering training intensity that could have an impact on the immune and hormonal salivary markers \[[@pone.0236669.ref028]\]. Secondly, the impact of blood contamination on the measurement of salivary hormones, associated with a minor injury in the oral cavity was not examined, as we did not use any biomarker for blood contamination. However, we believe that we adopted trustable procedures. All subjects in the study were checked on a regular base for oral health by the academy medical staff. Additionally, when we detected some values out of the range, they were excluded from the analysis.

[S1](#pone.0236669.s001){ref-type="supplementary-material"}

Supporting information {#sec028}
======================
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Click here for additional data file.

Firstly, the authors would like to thank all the athletes that volunteered to participate in this study, and the support from the Faculty of Sport Sciences and Physical Education, University of Coimbra.

10.1371/journal.pone.0236669.r001

Decision Letter 0

Tauler

Pedro

Academic Editor

© 2020 Pedro Tauler

2020

Pedro Tauler

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

16 Apr 2020

PONE-D-20-07349

Upper respiratory symptoms (URS) and salivary responses across a season in youth soccer players: a useful and non-invasive approach for predicting URS susceptibility and occurrence in young athletes

PLOS ONE

Dear Dr. Guerra Minuzzi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

All comments from the reviewers should be considered, mainly those regarding to the way results are reported and/or anylised. This comment includes also the general suggestion of showing some results in the abstract. Furthermore, the authors should clearly indicate how and where all data is available, as it is only indicated that \"it is available\".

We would appreciate receiving your revised manuscript by May 31 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Pedro Tauler, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a table of relevant demographic details, d) a statement as to whether your sample can be considered representative of a larger population, e) a description of how participants were recruited, and f) descriptions of where participants were recruited and where the research took place.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The study presented by Lopes et al. followed a substantial number of young athletes (n=57 players aged U15 to U19) over the course of a competitive season in order to characterize changes in salivary markers of immunity and hormonal changes. They hypothesized that athletes would exhibit different humoral and immune patterns throughout the season depending on their age. Furthermore, they hypothesized that these age-specific differences would be associated with differences in incidences of Upper Respiratory Symptoms (URS). This interesting premise is based on existing literature, showing associations between salivary markers of immunity and rate of URS in young athletes (Moraes et al. 2017), adults (Fahlman et al. 2017; Guilhem et al. 2015) and elderly (Akimoto et al. 2003). The authors report differences in salivary hormonal profile, along with markers of immunity between the age-groups and throughout the season. However, the authors suggest that the measured markers of oral immunity and hormonal status could be used to predict URS in young athletes, despite finding very weak correlations between URS incidence and their outcome measures (r\<0.200 for all). The authors should be careful in making bold statements that are not supported by their data. In addition, the data presented does not appear to be very novel.

Major Comments:

1\. Associations between salivary markers of immunity and URS presented by the authors are very weak. Both appear fairly stable over time, and correlation coefficients are well below the "r=0.300" limit for "weak" associations accepted in the literature. The authors should not extrapolate their results in suggesting it could be used to predict URS. Additionally, these results should be graphically depicted to improve the overall impact of the paper.

2\. Many researchers have argued that decrease in sIgA and sAA concentrations may not be associated with URS, until they reach a critically low value. Per example, Neville et al. discusses the use of a 40% reduction in the athlete's normal sIgA concentration as a threshold under which greater incidences of URS are observed. The authors describe sIgA and sAA as continuous variables, however did they also assess whether athletes reporting incidences of URS had lower than normal values of sIgA or sAA? Categorizing sAA and sIgA concentrations based on tertiles or quartiles may be strengthen their argument.

3\. No training intensity was available for this study, however one could hypothesize that different positions (GK vs defender vs striker etc...) may exhibit differences in the outcome measures. Did the author investigate this?

4\. The authors discuss the use of Testosterone/Cortisol ratio as a proxy measure of anabolic/catabolic state in the athletes. The authors collected saliva samples in the evening (18:00-19:00), where salivary cortisol was likely to be low, and thus this ratio would be more influenced by variations in sT. Furthermore sT is known to be negatively associated with overtraining (Maso et al. 2004), but it is not clear whether the authors saw a similar associations.

5\. The result section would benefit from having more graphical depiction of the collected data. Per example, it is difficult to judge whether the changes in URS throughout the season was associated with training volume without a figure (see comment 1).

Minor Comments:

1\. The authors describe that participants refrained from Caffeine and Food product; however no mention was made about alcohol consumption. Considering the differences in age amongst the participants, could this explain some of the changes seen in salivary Cortisol and Testosterone in the U19 group?

2\. Line 308: This sentence should be reworded

3\. Figure 1. Amylase is misspelled.

4\. Figure 1. Time effect is not represented

Reviewer \#2: General:

This is an interesting paper of potential value to the field. Strengths include the long-term monitoring period (whole soccer season), and high level (national division) participants. Weaknesses include infrequent sampling time-points reducing sensitivity to observe changes across time.

Specific:

Abstract: recommend including some actual quantitative data/results (for main/key outcomes) in abstract results section.

L78-87: Suggest change to order or mentioning these points. i.e. start with total number recruited, then number lost (dropout etc), then final number analysed.

Methods general (and subsequent results interpretation): salivary Cortisol and Testosterone are very susceptible to inaccuracy because of blood contamination in samples. It is recommended that this is screened for using biomarker assays (e.g. transferrin) because this cannot be detected visually.

L182-187: I do not fully understand the value this metric? If you want to normalise for comparison, why not express as % of mean monthly load? e.g. October volume was 113% of the season average?

L194: is % of total URS by age-group a fair and meaningful comparison? it would seem more appropriate to report number of episodes as % of team\... or more accurately, average number of episodes per player in each age group? And also the % of players experiencing at least 1 episode and/or those experiencing no episodes during the monitoring period/each time in each age group might be useful?

L337-338: or could it be a marker of overtraining or related to accumulated physiological stress, since OT is sometimes associated with a blunted HPA response?

L394: data not presented in results?? How does this compare to other age groups (i.e. what was the % in others) and other times of season? Any stats/sig differences?

L395: what about in January- in line with these points on high prevalence at this time in population?

L396: affection?

L413: direct stimulating effect is too strong an assertion to make based on this design and these data\... an association was observed is not the same as definite cause-effect relationship. Need to tone down language and inference here.

L418-419: but does need to be balanced against the desire to stimulate maximal physiological adaptation response?

L431: Then why not report the power (or Effect Size) statistics for your analyses in the results? You do mention ES in methods- this should be reported- and this will tell you if the power is OK or not.

Minor typos:

L118: \...prior to saliva collection\...

L121 3 min?

L165: Descriptive statistics

L196: \"There were found a significant inverse association\....\" would read better as \"A significant inverse association was found\....\"

L198: that there was a trend?

L205: this sentence does not make sense in current form (maybe \"show the pattern across time for the physiological parameters\" or something similar would be better?)?

L260: significantly?

L308: these data are in line with...

L320: observed pattern?

L322: the same as was observed?

L326: Northern

L333: as a potential

L362: or were not selected

L379: make players more likely to experience

L389: possibly because of

L402: out of

L427: acknowledged rather than assumed?

Reviewer \#3: Manuscript Number: PONE-D-20-07349

Title: Upper respiratory symptoms (URS) and salivary responses across a season in youth soccer players: a useful and non-invasive approach for predicting URS susceptibility and occurrence in young athletes

Reviewer\' Major Comments:

In this manuscript the authors aimed to examine the effect of a competitive season on salivary responses \[cortisol (sC), testosterone (sT), Testosterone/Cortisol ratio (sT/C), Immunoglobulin A (sIgA), sIgA secretion rate (srIgA), alpha-amylase (sAA)\] and upper respiratory symptoms (URS) occurrence in three teams of male soccer players (Under-15, Under-17 and Under-19 yrs.). The results show No differences were found for monthly training volume between teams. Incidence of URS was higher for the U15. Higher sT and srIgA were observed for the U19, lower sC were found for the U17 and sAA showed higher values for the U15 throughout the season. Monthly variations showed a decrease in sT in August compared to October and November for the U15. The U19 presented an increase in sC in March compared to February, sT/C were higher in March compared to February and April and sAA increased in March compared to September. Negative correlations, controlled for age group, were found between URS occurrence and srIgA (r=-0.190, p=0,001), sAA (r=-0.175, p=0.001) and sT (r=-0.115, p=0.036). The current study confirmed that youth soccer players show different age-related adaptive hormonal and immune responses to training and competition. The results show also that there is an association between training load (volume), mucosal immunity, hormone levels and URS.

The manuscript is well written and provides some new findings on this area. However, several issues must require attention.

In the abstract please give some significant results (e.g. values).

In the introduction some paragraphs must address what and why we need to know this and what the question you are addressing is and is it really that important.

In the introduction, first paragraph: which sport are the authors talking about ? soccer ?

Methods:

The authors have provided a detailed, yet concise, account of their study methods and experimental design. However, some precisions must be addressed:

\- Please give rationality for the n values (number of participants). How did you calculate that (power analysis)?

The discussion reflect what the authors found, how it relates to the literature. However there is a lack of what it means physiologically and there are some speculations.

The limitations of the study may state also the cost of such follow-up and the lack of nutritional measurements.
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Upper respiratory symptoms (URS) and salivary responses across a season in youth soccer players: a useful and non-invasive approach associated to URS susceptibility and occurrence in young athletes
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Dear Dr. Guerra Minuzzi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process by reviewer 2 about previous comments not completely clarified or revised by the authors.

Please submit your revised manuscript by Aug 03 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Pedro Tauler, Ph.D.

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have appropriately responded to my concerns. The updated manuscript provides novel insight on the immune function of youth soccer players

Reviewer \#2: Thank you for addressing most of my comments. I have the following comments that require further consideration:

Regarding the following comment and author response: Abstract: recommend including some actual quantitative data/results (for main/key outcomes) in abstract results section.

Author response 1: We agreed with the recommendation. However, we opted for a descriptive presentation of the results in the abstract, as we think it would be the clearest way.

FURTHER COMMENT ON THIS:

This reviewer does not agree with this response. The current presentation is not informative to readers. P values and correlations are of little use or meaning without some actual data to benchmark this against. It is essential to include some data (not for all, but for at least THE most important measure).

Regarding the following comment and author response: Methods general (and subsequent results interpretation): salivary Cortisol and Testosterone are very susceptible to inaccuracy because of blood contamination in samples. It is recommended that this is screened for using biomarker assays (e.g. transferrin) because this cannot be detected visually.

Author response 1: Thanks for the remark. All subjects in the study were checked on a regular base for oral health by the academy medical staff. We take every care concerning to all Salimetrics indications for saliva sampling. The variation of hormonal and immune results is under expected values and in the range of the commercial kits used for analyses. When detected, some values out of the range, were excluded from analysis. Although we did not use any biomarker for blood contamination, we believe that we met all care possible.

FURTHER COMMENT ON THIS:

"All of the Salimetrics indications"? This is not completely clear, but blood 'contamination' is quite normal and not something that can be determined only by oral health per se (so the regular check-ups are not sufficient to protect against this. Many players could be perfectly healthy and normal in terms of oral check-ups etc, but can still provide samples with blood contamination sufficient to affect accuracy of T and C measured in these samples). Importantly, this can vary across the day and day-to-day within the same person. You will not necessarily be able to pick this up by whether or not the values are in the normal range, it could still be present and could still skew the results of a particular sample. In summary, you cannot be certain if blood contamination was present or not in each sample with the methods you have employed and there remains the possibility that this could have caused some inaccuracies in the results you report. This must be noted and acknowledged in the limitations section (and hence be careful with any conclusions that you draw based on these particular results).

Regarding the following comment and author response: L182-187: I do not fully understand the value this metric? If you want to normalise for comparison, why not express as % of mean monthly load? e.g. October volume was 113% of the season average?

Author response 1: We thank the reviewerfor the opportunity to clarify the presentation of the seasonal variation in the training volume observed in the 3 teams. We calculate the mean seasonal volumes(training and match)and the monthly variation around this value(Figure 1). Regarding U15 group we observed that the highest value was in October (12.3% above), whereas the U17 and U19 showed higher volumes in August, respectively 18,6% and 14,5% above de seasonal mean volume.The seasonal variation of training was low, for both teams (CV= 9,7%, 10,3% and 11,3%) for U-15, U17 and U-19, respectively.

FURTHER COMMENT ON THIS:

Thanks for the clarification. This is not completely clear in the accompanying text however (i.e. L203-205 of the revised manuscript). I would recommend adding some clarification (i.e. to better explain that the 12.3% represents the % increase above average... so perhaps it would be clearer as follows (or something similar)?

"Regarding the monthly distribution of exercise volume in each group, the U15 highest percentages emerged in October (12.3% above season average), whereas the relative picture for both U17 (18.6% above season average) and U19 (14.5% above season average) was in August."

Reviewer \#3: Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) (Limit 100 to 20000 Characters)

The authors respond to all our comments and suggestions. Congratulations.
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear,

We would like to thank the reviewers and editor for their new careful review of the manuscript. They raise another important issue and their inputs are very helpful for improving the manuscript. We now submit a new revised version of the article. We hope that the reviewers and editor will find the new version of the manuscript satisfactory.

Here, we present a response to each point raised by the reviewer 2. Also, we clarify the text and the changes are in red in the manuscript version upload.

6\. Review Comments to the Author

Reviewer \#1: The authors have appropriately responded to my concerns. The updated manuscript provides novel insight on the immune function of youth soccer players

Reviewer \#2: Thank you for addressing most of my comments. I have the following comments that require further consideration:

Regarding the following comment and author response: Abstract: recommend including some actual quantitative data/results (for main/key outcomes) in abstract results section.

Author response 1: We agreed with the recommendation. However, we opted for a descriptive presentation of the results in the abstract, as we think it would be the clearest way.

FURTHER COMMENT ON THIS:

This reviewer does not agree with this response. The current presentation is not informative to readers. P values and correlations are of little use or meaning without some actual data to benchmark this against. It is essential to include some data (not for all, but for at least THE most important measure).

Author response 2: Thanks for the remark and the opportunity to improve this section. We hope that we understand well your vision, and we added the most critical data in the abstract, given it more informative to the readers! We choose to use the percental variation of hormonal and immune parameters values during the season. But, if necessaire, we are open to change and also present the absolute values of the data.

Regarding the following comment and author response: Methods general (and subsequent results interpretation): salivary Cortisol and Testosterone are very susceptible to inaccuracy because of blood contamination in samples. It is recommended that this is screened for using biomarker assays (e.g. transferrin) because this cannot be detected visually.

Author response 1: Thanks for the remark. All subjects in the study were checked on a regular base for oral health by the academy medical staff. We take every care concerning to all Salimetrics indications for saliva sampling. The variation of hormonal and immune results is under expected values and in the range of the commercial kits used for analyses. When detected, some values out of the range, were excluded from analysis. Although we did not use any biomarker for blood contamination, we believe that we met all care possible.

FURTHER COMMENT ON THIS:

"All of the Salimetrics indications"? This is not completely clear, but blood 'contamination' is quite normal and not something that can be determined only by oral health per se (so the regular check-ups are not sufficient to protect against this. Many players could be perfectly healthy and normal in terms of oral check-ups etc, but can still provide samples with blood contamination sufficient to affect accuracy of T and C measured in these samples). Importantly, this can vary across the day and day-to-day within the same person. You will not necessarily be able to pick this up by whether or not the values are in the normal range, it could still be present and could still skew the results of a particular sample. In summary, you cannot be certain if blood contamination was present or not in each sample with the methods you have employed and there remains the possibility that this could have caused some inaccuracies in the results you report. This must be noted and acknowledged in the limitations section (and hence be careful with any conclusions that you draw based on these particular results).

Author response 2: We thank the opportunity, and we followed the reviewer advice and suggestion. We added this information clarifying that the samples have not been screened for possible blood contamination which is a limitation of the study.

Regarding the following comment and author response: L182-187: I do not fully understand the value this metric? If you want to normalise for comparison, why not express as % of mean monthly load? e.g. October volume was 113% of the season average?

Author response 1: We thank the reviewer for the opportunity to clarify the presentation of the seasonal variation in the training volume observed in the 3 teams. We calculate the mean seasonal volumes(training and match)and the monthly variation around this value(Figure 1). Regarding U15 group we observed that the highest value was in October (12.3% above), whereas the U17 and U19 showed higher volumes in August, respectively 18,6% and 14,5% above de seasonal mean volume.The seasonal variation of training was low, for both teams (CV= 9,7%, 10,3% and 11,3%) for U-15, U17 and U-19, respectively.

FURTHER COMMENT ON THIS:

Thanks for the clarification. This is not completely clear in the accompanying text however (i.e. L203-205 of the revised manuscript). I would recommend adding some clarification (i.e. to better explain that the 12.3% represents the % increase above average... so perhaps it would be clearer as follows (or something similar)?

"Regarding the monthly distribution of exercise volume in each group, the U15 highest percentages emerged in October (12.3% above season average), whereas the relative picture for both U17 (18.6% above season average) and U19 (14.5% above season average) was in August."

Author response 2: We agree and thanks the reviewer. The correction in the text was done following the reviewer advice.

Reviewer \#3: Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) (Limit 100 to 20000 Characters)

The authors respond to all our comments and suggestions. Congratulations.
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Dear Dr. Guerra Minuzzi,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Pedro Tauler, Ph.D.

Academic Editor
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**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: Thanks
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Dear Dr. Minuzzi:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.
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PLOS ONE Editorial Office Staff
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Dr. Pedro Tauler

Academic Editor
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